Menu Back toSession-0102-Future-Direction-of-Global-Drug-Development-With-ICH-E17-Guideline-Focusing-on-MRCTs

The 7th DIA China Annual Meeting


Session 0102 Future Direction of Global Drug Development With ICH E17 Guideline Focusing on MRCTs

Session Chair(s)

Yoshiaki  Uyama, PhD

Yoshiaki Uyama, PhD

  • Director, Office of Medical Informatics and Epidemiology
  • Pharmaceuticals and Medical Devices Agency (PMDA), Japan

General principles on planningdesigning Multi-Regional Clinical Trials E17

Speaker(s)

Lih-Jiuan  Hsu

Impacts of E17 Guideline for Drug Review and Approval in Taiwan

Lih-Jiuan Hsu

  • Director, Center of Consultation
  • Center for Drug Evaluation, Taiwan
Patrick  Brady, PharmD

Global Drug Development Impact of ICH E17 Guideline_An Industry Perspective

Patrick Brady, PharmD

  • Vice President, Regulatory Affairs Head, Regulatory Policy and Intelligence
  • Bayer AG Pharmaceuticals, Germany

Contact us

For exhibition, advertising and hosting inquiry, please contact:
Jean XU: jxu@kellencompany.com, or Sofie Peeters: speeters@kellencompany.com
Tel: +86 10 5923 1096

For general inquiry, please contact DIA China office:
dia@diachina.org
Tel: +86 10 5704 2650